267 results about "Immune effector" patented technology

The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.

The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule.

The invention provides a specific T cell receptor targeting KRAS G12V mutant epitope peptide (such as an amino acid sequence as shown in SEQ ID NO: 2) and anti-tumor application of the specific T cell receptor. The specific T cell receptor is composed of two peptide chains alpha and beta and can be specifically combined with a VVGAVGVGK-HLA-A * 11: 01 compound. The invention also provides an antigen binding fragment of the specific T cell receptor, a nucleic acid sequence for coding the T cell receptor, a vector containing the nucleic acid sequence, an engineered cell for expressing the T cell receptor, a composition containing the T cell receptor and application thereof. In addition, the invention also provides a method for screening the KRAS G12V specific T cell receptor. The specific T cell receptor and the antigen binding fragment thereof provided by the invention can be used as an immune effect activator to stimulate the immune response of a body, so that the effect of resisting diseases such as tumors and the like is achieved.

The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., immune effector cells such as T cells, B cells, natural killer cells, and dendritic cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) in subjects receiving donor cells. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer suppress alloreactive donor cells. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.

Feline, canine, and equine antibody variants and uses thereof, as well as compositions and methods for improving therapeutic monoclonal antibodies by modulating immune effector functions and antibody variants using those methods and compositions.

The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.

Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-ROR-1 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.

Compositions and methods for treating diseases associated with expression of a cancer associated antigen are disclosed. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, SHP inhibitory molecules, vectors encoding the same, and recombinant immune effector cells comprising the CARs and SHP inhibitory molecules. Methods of administering a genetically modified immune effector cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen and a SHP inhibitory polypeptide are also disclosed.

The present application relates to genetically modified immune cells to express a recombinant human CD16 protein having an enhanced anti-shear ability with the presence of addition, deletion, substitution, or any combination of addition, deletion, substitution of one or more amino acids compared to a wild-type amino acid sequence.

The invention provides a live pig immune function prediction system and method based on artificial intelligence. The system comprises a detection device used for detecting intestinal flora detection data corresponding to a plurality of omics and detection result data of a plurality of metabolic markers of a live pig in a stress state; the edge optimization decision device is used for performing feature extraction according to the detection result data to obtain metabolic feature data; the prediction and display device is used for simulating an expression relationship between the activity of a key metabolic enzyme and immune effector molecules of the live pig in a stress state according to the intestinal flora detection data to obtain metabolic-immune interaction data, storing the metabolic-immune interaction data in a metabolic-immune database, and displaying the metabolic-immune interaction data in the metabolic-immune database. According to the metabolism characteristic data and metabolism and immunity interaction data stored in a metabolism and immunity database, determining a dose effect relationship between the functional amino acid and the immunity phenotype to obtain metabolism spectrum characteristics of the live pig in a stress state, and according to the metabolism spectrum characteristics, predicting, generating and displaying an amino acid ratio or daily ration intervention strategy.

The present disclosure provides an anti-IL13RA2 single domain antibody (e.g., a VHH domain antibody), and a chimeric antigen receptor (CAR) that binds IL13RA2, the chimeric antigen receptor comprising: the anti-IL13RA2 single domain antibody in an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Immune effector cells transduced with the disclosed CAR constructs can be used in cancer immunotherapy.

The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.

Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-ROR-1 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.

The invention relates to the technical field of genetic engineering antibodies, in particular to a bispecific antibody combined with BCMA and CD3 as well as a preparation method and application of the bispecific antibody. The invention provides a bispecific antibody which can be combined with BCMA and CD3 at the same time, has a specific targeting effect and can efficiently excite oriented immune response. The bispecific antibody well retains the biological functions of an anti-CD3 antibody and an anti-BCMA antibody, realizes that one bispecific antibody molecule simultaneously has an excellent BCMA and CD3 targeted binding biological function, can build a bridge between tumor cells and immune effector cells, effectively activates the immune effector cells and oriented immune response, and has a good application prospect. The tumor cell killing effect of immune cells is remarkably enhanced, the target cell killing efficiency is high, the ADCC effect is reduced to the maximum degree, high safety is achieved, and good application prospects are achieved in tumor immunotherapy.

The present application provides compositions and methods of use relating to modified immune effector cells for use in the treatment of diseases such as cancer. The modified immune effector cells disclosed herein can be engineered to exhibit decreased expression and or activity of immune adhesion / costimulatory molecules, MHC proteins, and / or T cell receptors. The modified immune effector cells can also comprise chimeric antigen receptors.

The present disclosure features modified immune effector cells (e.g., T cells or NK cells) having increased resistance to inhibition of an immunosuppressive agent relative to unmodified immune effector cells, compositions comprising the same, and methods of using the same.

Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

The present invention relates generally to the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.

The present invention provides methods of making immune effector cells (e.g., T cells, NK cells) that express chimeric antigen receptors (CARs), and compositions produced by such methods, and therapeutic uses thereof for the treatment of autoimmune diseases or disorders.

The current disclosure relates to targeted delivery of agents to T cells and / or NK cells. Highly suitable targeting domains were meticulously identified that allow for an agent, such as DNA and / or RNA, to be delivered to T cells and / or NK cells. As shown, when lipid nanoparticles were provided with such a targeting domain, nucleic acid comprised in said lipid nanoparticles was highly efficiently and specifically delivered. This allows for engineering of T cells and / or NK cells, highly useful in medical treatments for cancer.

Disclosed herein are methods of gene editing, or endogenous suppression, of cytokines / chemokines / transcription factors secreted from chimeric antigen receptor (CAR)-bearing immune effector cell such as CAR-T cells for the mitigation of cytokine release syndrome and / or CAR-T associated neuropathy. These methods involve insertion of the CAR into a locus of a cytokine gene, blocking its expression. Also disclosed herein are (CAR)-bearing immune effector cells with CARs inserted into a locus of a cytokine gene, and methods of treatment of diseases with immunotherapy with a reduced incidence of cytokine release syndrome and / or CAR-T associated neuropathy.

The present disclosure provides compositions and methods comprising recombinant particles suitable for specifically delivering one or more chimeric antigen receptors to immune effector cells in vivo.

The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Provided are anti-Claudin-6 antibodies (e.g., VHH domain antibodies), and a chimeric antigen receptor (CAR) that binds to Claudin-6 comprising same in an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Immune effector cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.

The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and / or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and / or treatment of various diseases.

The present invention relates to combination therapies for modulating the tumor microenvironment and enhancing infiltration of immune cells into the tumor microenvironment with a bispecific anti-EGFR / c-Met antibody in combination with a PD-(L) 1 axis inhibitor. The invention also relates to combination therapies for inhibiting EGFR and MET signaling pathways in tumor cells, and targeting tumor cells expressing EGFR and MET to be disrupted by immune effector cells such as natural killer cells and macrophages by antibody dependent cytotoxicity (ADCC) and cell gnawing mechanisms, respectively.

The present disclosure provides methods of rapidly manufacturing genetically modified immune effector cells, such as T cells. The method allows fast (llt; 1 day) to produce genetically modified immune effector cells, such as CAR T cells.

The invention relates to a CD19 and CD70 targeted double-target chimeric antigen receptor and application thereof, the CD19 and CD70 targeted double-target chimeric antigen receptor comprises an extracellular antigen binding domain, a hinge region, a transmembrane domain, an intracellular costimulatory domain and an intracellular signal transduction domain, and the extracellular antigen binding domain has specific binding ability to CD19 and CD70. The double-target chimeric antigen receptor structure has a treatment effect of targeting double antigens or single antigens, can be used for preparing immune effector cells targeting CD19 and CD70, and provides a treatment or improvement approach for diseases related to CD19 and CD70 double expression or CD19 / CD70 single expression.